Native-like airway mucus model mimicking the composition and viscosity of healthy human airway mucus.
Composed of:
- 20.0 mg/ml mucin
- 4.78 mg/ml NaCl
Disease-specific airway mucus model replicating the thicker, more viscous mucus and higher salinity of cystic fibrosis patients.
Composed of:
- 25.0 mg/ml mucin
- 7.01 mg/ml NaCl
Advantages
Replicates the natural composition and properties of airway mucus
Drug permeability studies, bacterial colonization research, microbiota growth, and targeted evaluation of drug efficacy for respiratory applications
Standardized, reproducible, and ready-to-use mucus models that accelerates high-throughput drug and microbiome research and seamlessly integrates into existing workflows—saving time and streamlining discovery
Reduce the need for animal testing by mimicking human mucus, aligning with ethical and regulatory principles
Publications
O.V. Garbero, L. Sardelli, C.S. Butnarasu, E. Frasca, C. Medana, F. Dal Bello, S. Visentin. Tracing the path of Quorum sensing molecules in cystic fibrosis mucus in a biomimetic in vitro permeability platform. Scientific Reports, 2024, 14(1): 25907.
C.S. Butnarasu, O.V. Garbero, P. Petrini, L. Visai, Sonja Visentin. Permeability Assessment of a High-Throughput Mucosal Platform. Pharmaceutics, 2023, 15(2):380.
C.S. Butnarasu, P. Petrini, F. Bracotti, L. Visai, G. Guagliano, A. Fiorio Pla, E. Sansone, S. Petrillo, S. Visentin. Mucosomes: Intrinsically Mucoadhesive Glycosylated Mucin Nanoparticles as Multi-Drug Delivery Platform. Advanced Healthcare Materials, 2022, 11(15): e2200340.
D. P. Pacheco, F. Bertoglio, C.S. Butnarasu, N. Suárez Vargas, G. Guagliano, A. Ziccarelli, F. Briatico-Vangosa, V. Ruzzi, S. Buzzaccaro, R. Piazza, S. van Uden, E. Crotti, S. Visentin, L. Visai, P. Petrini. Heterogeneity Governs 3D-Cultures of Clinically Relevant Microbial Communities. Advanced Healthcare Materials, 2023.
D. P. Pacheco, C.S. Butnarasu, F. Briatico-Vangosa, L. Pastorino, L. Visai, S. Visentin, P. Petrini. Disassembling the complexity of mucus barriers to develop a fast screening tool for early drug discovery. Journal of Materials Chemistry B. 2019, 7, 4940-4952.
C.S. Butnarasu, N. Barbero, D. P. Pacheco, P. Petrini, S. Visentin. Mucin binding to therapeutic molecules: The case of antimicrobial agents used in cystic fibrosis. Int J Pharm, 2019, 564:136-144.
C.S. Butnarasu, G. Caron, D. P. Pacheco, P. Petrini, S. Visentin. Cystic Fibrosis Mucus Model to Design More Efficient Drug Therapies. Mol Pharm, 2022, 19(2): 520-531.
L. Pedersoli, S. Zhang, F. Briatico-Vangosa, P. Petrini, R. Cardinaels, J. den Toonder, D. P. Pacheco. Engineered modular microphysiological models of the human airway clearance phenomena. Biotechnol Bioeng, 2021, 118(10): 3898-3913.